

Caveolin-1 and dynamin-2 overexpression is associated with the progression of bladder cancer

SADAF AZAD RAJA¹, SYED TAHIR ABBAS SHAH¹, AAMIRA TARIQ¹, NAZIA BIBI¹,
KALSOOM SUGHRA², ARZU YOUSUF³, ATHAR KHAWAJA³, MUHAMMAD NAWAZ⁴,
ARSHAD MEHMOOD⁴, MUHAMMAD JADOON KHAN¹ and ALAMDAR HUSSAIN¹

¹Department of Biosciences, COMSATS University Islamabad, Islamabad 45550; ²Department of Biochemistry and Biotechnology, University of Gujrat, Gujrat 50700; ³Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad 44790; ⁴Armed Forces Institute of Urology, Rawalpindi 46000, Pakistan

Received September 14, 2018; Accepted April 3, 2019

DOI: 10.3892/ol.2019.10310

Abstract. Caveolae-mediated endocytosis regulates cell adhesion and growth in an anchorage-dependent manner. Studies of the endocytic function of caveolae have suggested a wide-ranging list of cargoes, including a number of receptors and extracellular proteins, ligands and nutrients from the extracellular matrix. Disruption of the processes of caveolae-mediated endocytosis mediated by signaling proteins is critical to cellular integrity. Caveolin-1 and dynamin-2 are the 2 major proteins associated with endocytotic function. Mechanistically, dynamin-2 has a co-equal role with caveolin-1 in terms of caveolae-derived endosome formation. Recent studies have revealed the pathological outcomes associated with the dysregulation of caveolin-1 and dynamin-2 expression. Increased expression levels of the gene for caveolin, *Cav-1*, resulting in augmented cellular metastasis and invasion, have been demonstrated in various types of cancer, and overexpression of the gene for dynamin-2, *DNM2*, has been associated with tumorigenesis in cervical, pancreatic and lung cancer. An increased expression of *Cav-1* and *DNM2* is known to be associated with the invasive behavior of cancer cells, and with cancer progression. Furthermore, it has been previously demonstrated that, in caveolar assembly and caveolae mediated endocytosis, *Cav-1* interacts directly with *DNM2* during the processes. Altered expression of the 2 genes is critical for the normal function of the cell. The expression patterns of *Cav-1* and *DNM2* have been previously examined in bladder cancer cell lines, and were each demonstrated to be overexpressed. In the present study, the expression levels of these 2 genes in bladder cancer samples were quantified.

The gene expression levels of *Cav-1* and *DNM2* were identified to be increased 8.88- and 8.62-fold, respectively, in tumors compared with the normal controls. Furthermore, high-grade tumors exhibited significantly increased expression levels of *Cav-1* and *DNM2* (both $P < 0.0001$) compared with the low-grade tumors. In addition, compared with normal control samples, the expression of the 2 genes in tumor samples was observed to be highly significant ($P < 0.0001$), with a marked positive correlation identified for the tumors (Pearson's correlation coefficient, $r = 0.80$ for the tumor samples vs. $r = 0.32$ in the normal control samples). Taken together, the results of the present study demonstrated that the overexpression of *Cav-1* and *DNM2* genes, and a determination of their correlation coefficients, may be a potential risk factor for bladder cancer, in addition to other clinical factors.

Introduction

Caveolae are small bulb-like invaginations (50-80 nm in diameter) in the plasma membrane, with a diverse array of signal transduction functions (1-3). Functioning as a signal-transducing platform, caveolae are actively involved in the transcellular transport of ligands and receptor molecules, forming a specialized transporting system that maintains the lipid content of plasma membranes via transcytosis (4). Caveolae have been implicated as crucial entities for cell-cell communication via the endocytosis of signaling molecules, in addition to their role as signaling platforms where membrane receptors, including G-protein-coupled receptors, reside. Disrupted signaling through key caveolar proteins results in various pathologies, including cardiomyopathy diseases, lipodystrophy, and, most importantly, cancer (5). Caveolar proteins exert their dynamic role in maintaining cell growth, cell protection and overall cell function (6). Caveolae consist of complexes comprising different transmembrane proteins, including caveolin, cavin, dynamin-2, EH-domain containing 2 protein and protein kinase C and casein kinase substrate in neurons protein 2, among which caveolins are the core functional proteins (7). Cavins and caveolins (1-3) are the fundamental proteins that mediate caveolar organization. Caveolins provide a signaling platform for the coordination

Correspondence to: Dr Syed Tahir Abbas Shah, Department of Biosciences, COMSATS University Islamabad, 110 Academic Block III, COMSATS University Islamabad, Park Road, Chak Shahzad, Tarlai Kalan, Islamabad 45550, Pakistan
E-mail: syedtaahirabbas@comsats.edu.pk

Key words: bladder cancer, caveolin-1, dynamin-2

and interaction of different growth factor receptors, protein kinases and various intracellular signaling molecules (8). Dynamin-2, the product of the dynamin 2 (*DNM2*) gene, is a GTPase that directly interacts with caveolin-1, the product of the caveolin-1 (*Cav-1*) gene, mediating membrane scission, leading to endosome formation (9). Caveolin-1 and dynamin-2 are the key regulators of clathrin-independent endocytosis (10).

Among the caveolin proteins, caveolin-1 (molecular mass, ~21 kDa) is known to be a key protein of the caveolae complex that has an important role in maintaining cell metabolism, anchorage-dependent growth, motility and signaling, and the cellular microenvironment (11). In fulfilling these crucial roles in cell growth and maintenance, the altered expression and function of caveolin-1 is associated with oncogenic cell transformation, cell metastasis, invasion and tumorigenesis. Enhanced expression of *Cav-1* promotes tumor growth and invasion, resulting in the metastasis of human breast cancer cells (12). Knockdown of *Cav-1* was demonstrated to inhibit tumor growth and metastasis (13). Dynamin-2 (molecular mass ~100 kDa) is a GTPase that is actively involved in membrane fission during the endocytosis of cell-surface receptors and signaling molecules. The endosomes, also termed 'caveosomes', thus formed are continually recycled to the cell surface (14). This mechanism of protein expression on the cell membrane is disrupted in cancer cells. Dynamin-2 protein dysfunction results in the dysregulation of endosome recycling, causing an imbalanced expression of regulatory growth factor receptors, including epidermal growth factor receptor, on the cell surface, promoting aberrant cell growth, invasion and proliferation (15). Overexpression of *Cav-1* and *DNM2* has been demonstrated to be involved in cell lines of various types of cancer, including pancreatic, colon, lung, breast and prostate cancer (13,16-22).

Bladder cancer is the ninth most common cancer worldwide. Of all incident cases of different types of cancer in the Pakistani population during the year 2012 (n=148,041), the incidence rate of bladder cancer in the male population was 3,020, which was increased compared with that in the female population (n=946) (23). In muscle-invasive bladder cancers, 58 genetic mutations have been demonstrated to be causative factors for cancer progression in the bladder, and these are associated with low survival rates (24). There are a number of genetic alterations associated with bladder cancer progression. Overexpression, and genetic mutation, of several different genes that are critical in cell cycle regulation, apoptosis, signal transduction and angiogenesis have been identified, among which mutants of tumor protein (p53), fibroblast growth factor 3, Janus kinase/signal transducers and activator of transcription, hypoxia-inducible factor, retinoblastoma protein 1, HRas proto-oncogene, GTPase (also known as transforming protein p21), tuberous sclerosis 1, telomerase reverse transcriptase, and ubiquitin carboxyl-terminal hydrolase BAP1 have been identified and studied (24-26). Furthermore, numerous other previously identified genetic alterations are associated with a poor prognostic outcome, and these are currently undergoing validation (27). Regulatory genes that are involved in cell cycle regulation and apoptosis have been validated as combined prognostic markers for bladder cancer, although these are under investigation for use as single markers associated with urothelial carcinoma (28). However, genes/proteins that are involved in cell surface communication with the extracellular environment, cell-to-cell communication,

endocytosis, and exocytosis are far more susceptible to cancer development compared with intercellular proteins, particularly caveolar proteins (29). The upregulation of caveolar proteins has been demonstrated for various different types of cancer, whereas only a few cancer types have been associated with their downregulation (30,31). Despite the contradictory roles identified for caveolin-1 in different types of cancer, overexpression of *Cav-1* has been described for the majority of human cancer types. Previous studies investigating the overall clinical value of *Cav-1*, and its association with tumor aggressiveness, size, stage, grade and differentiation, suggest that it may serve as a good candidate prognostic marker for a majority of cancer types, including bladder cancer (32,33). By contrast, the gene expression of *DNM2*, and its association with cancer progression, has yet to be fully investigated. However, the identification and validation of the prognostic panel of disease markers for bladder cancer is required. A number of studies have explored the expression profiling of bladder cancer in humans, in which genome coding sequences were decoded for evaluating genetic alterations associated with the disease, and subsequently, the prognostic marker panel could be selected. However, one disadvantage in terms of ensuring its reproducibility is that this widely applied approach is highly expensive (34-36).

Bladder cancer, based on its metastatic ability to spread to other parts of the body, is divided into 4 stages (stages I-IV) according to the tumor-node-metastasis (TNM) staging system (37). Physiologically, bladder tumors are essentially categorized into 2 grades: Low-grade papillary urothelial carcinoma and high-grade papillary urothelial carcinoma, according to the World Health Organization/International Society of Urological Pathology classification system, published in 2004 (38). Previous studies have demonstrated altered expression levels of *Cav-1* and *DNM2* in bladder cancer cell lines (33,39-41). Therefore, the present study aimed to investigate the degree of correlation of gene expression in comparing between the *Cav-1* and *DNM2* genes in bladder cancer tumor samples, specifically with respect to the progressiveness of the tumors. The results obtained revealed that the significant correlation between the overexpression of *Cav-1* and *DNM2* in bladder tumors was critical for cancer development, and for tumor stage and grade progression. The overexpression of these 2 genes could be considered clinically relevant and may prove as candidate risk factors for bladder cancer progression.

Materials and methods

Tumor sampling. The present study was approved by the Ethical Review Board of COMSATS University Islamabad (Islamabad, Pakistan; approval no. CIIT/Bio/ERB/18/76). Samples were collected between July, 2015 and March 2017. Tumor and normal tissue samples were excised from patients with bladder cancer post-surgery, following transurethral resection of bladder tumor (TURBT) surgery. Signed written consent was obtained from all the patients involved in the present study (n=66; male=47; female=19). The patients' age ranged between 30 and 65 years and the median age was 43 years. The histopathological histories of the patients were confirmed by the Pathology Laboratory, Pakistan Institute of Medical Science (PIMS) (Islamabad, Pakistan) and Shifa International Hospital (Islamabad, Pakistan). Paired samples of tumors with their

Table I. Primer sequence used for reverse transcription quantitative polymerase chain reaction analysis.

Transcript	Forward primer	Reverse primer	Length, bp	Primer location GRCh38.p12
<i>Cav-1</i> (NM_001753.4)	GACGTGGTCAAGAT TGACTTGA	GACGAAATACTGGT TTTACCG	120	(Chr7: 116526678..116526689// 116558946-116558956) (Chr7: 116559032-116559053)
<i>DNM2</i> (NM_001005360.2)	GCATGGGCACGCCA CATCTG	GCTGCTGTCCCTGG AGAAGGAG	119	(Chr19: 10783083-10783102) (Chr19: 10786623-10786644)

Cav-1, caveolin-1; DNM2, dynamin-2; chr, chromosome.

adjacent normal tissues were obtained. Normal tissue samples were used as controls. The tumor staging and grading was assessed by the team of urologists at Pathology Laboratory, Department of Urology, PIMS. The TNM system of staging was applied for evaluation of the tumor stage. The revised guidelines by National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer and American Society of Clinical Oncology (ACSO) 2015-2018 were followed during grading and staging of tumor samples (42).

Reverse transcription quantitative polymerase chain reaction (RT-qPCR). Tissues extracted from the patients were stored in RNeasy® (Ambion; Thermo Fisher Scientific, Inc.) at 4°C in a refrigerator. RNA extraction was performed using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) reagent according to the manufacturer's protocol (43). Subsequently, cDNA synthesis was performed, followed by RNA quantification. The minimum concentration of RNA used in these experiments was 1-2 µg for cDNA synthesis. Thermo Scientific RevertAid First Strand cDNA Synthesis kit was used for cDNA synthesis (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. The PrimerQuest tool (Integrated DNA Technologies, Inc.) was used to design the primers, which were subsequently altered manually to meet the required specifications for RT-qPCR. The forward primer for *Cav-1* (NM_001753.4) was designed to span exon 2 and the junction with exon 3, and the reverse primer was selected from exon 3, whereas the primer set for *DNM2* (NM_001005360.2) was designed based on the intron flanking exons 6 and 7 (Table I). Tubulin 3 was used as an endogenous marker for evaluating changes in the expression levels of *Cav-1* and *DNM2*. *In silico* PCR (University of California Santa Cruz) was performed to ensure amplification of the 2 target genes. RT-qPCR using the Applied Biosystems™ StepOnePlus™ RealTime PCR system (Applied Biosystems, Inc.; Thermo Fisher Scientific, Inc.) was performed for the *Cav-1* and *DNM2* genes under standard conditions, as specified by the protocol. The concentration of cDNA was rounded up to 2 µg/µl for each sample, and the total volume per reaction was adjusted to 25 µl with SYBR™ Green Master mix (Maxima Syber Green/ROX qPCR Master mix; Thermo Fisher Scientific, Inc.). The RT-qPCR conditions consisted of an initial incubation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 30 sec, an annealing with primer at 57°C for 30 sec and extension at 72°C for 30 sec. Final extension was performed at 72°C for 10 min.

Gene expression analysis. The relative expression levels of *Cav-1* and *DNM2* were calculated using the 2^{-ΔΔC_q} method (44). Using *TUBB3* as the control reference gene (45), relative differences in gene expression were obtained in terms of the fold increase in expression. To obtain the expression data, the C_q values of the *Cav-1* and *DNM2* genes were normalized against the C_q value for endogenous *TUBB3*.

Statistical analysis. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.) and OriginPro 2017 (OriginLab Corporation) software. Contingencies of the patients' data were determined using Fisher's exact two-tailed test, and the correlation between the gene expression patterns was assessed using Pearson's correlation coefficient test. Depending on the experiment, the statistical significance of the resulting data was determined using either the Wilcoxon test or one way analysis of variance followed by the Tukey's honest significant difference post-hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Tumor histopathology. Tumor staging was evaluated by the Pathology Laboratory of PIMS, according to the TNM system but incorporating the revisions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer and ACSO 2015-2018 (42). Distribution of the tumor grade and stage data by sex and age groups was statistically analyzed (Table II). In October 2017, The Cancer Genome Atlas (TCGA) published the prevalence and incidence rates of bladder cancer (https://cancergenome.nih.gov/newsevents/newsannouncements/bladder-cancer_2017), which was increased in the male population compared with females, and, in terms of underlying causes, smoking was demonstrated to be the major factor in that study (46). A comprehensive molecular characterization study was also performed by TCGA research network, which described the genetic alterations associated with bladder cancer (24). In the present study, a significant difference was identified in terms of the pathology between the sexes in the different age groups (P=0.0024; Table II). A number of different diseases were identified in patients from both age groups, but their associations with bladder cancer were not statistically significant. Conversely, the risk factors of active smoking (P=0.0135) and passive smoking (P=0.0316) were identified to be significantly associated with bladder cancer (Table III).

Table II. Tumor stage and grade data distribution by sex and age.

Patient data	Age groups, years		P-value
	≤50	>50	
Sex			
Male	32	15	0.0024 ^a
Female	12	7	
Histology (%)			
Tumor grade			
High	20 (45.4)	12 (55.0)	0.6032
Low	24 (55.0)	10 (45.4)	
Tumor stage			
Stage I			
Male	16 (50.0)	4 (27.1)	0.0235 ^a
Female	1 (8.3)	4 (57.1)	
Stage II			
Male	12 (38)	2 (13.3)	0.0441 ^a
Female	1 (8.3)	3 (42)	
Stage III (%)			
Male	4 (12.5)	9 (60.0)	0.0116 ^a
Female	10 (84.0)	0 (0.0)	


^aP-value <0.05.

Figure 1. Comparison of Cav-1 and DNM2 expression in tumor and adjacent normal bladder tissues using the Wilcoxon test. ****P<0.0001. Cav-1, caveolin-1; DNM2, dynamin-2.

Cav-1 and DNM2 expression. In the tumor samples, the expression levels of *Cav-1* and *DNM2* were experimentally analyzed using RT-qPCR. The expression of *Cav-1* in the tumor samples was increased by 8.88-fold overall compared with the normal tissues. Similarly, the expression level of *DNM2* was also increased by 8.6-fold compared with the normal adjacent, or control, tissues (P<0.001). As demonstrated in Fig. 1, boxplots of normalized (mean ± standard error of the mean) gene expression of *Cav-1* and *DNM2* revealed a significant increase in gene expression in tumor tissues compared with the adjacent normal tissue. Previous studies also demonstrated increased expression levels of *Cav-1* and *DNM2* in different

Table III. Disease history and smoking habits in bladder cancer.

Patient data	Age groups, years		P-value
	≤50	>50	
Sex			
Male	32	15	0.0024 ^b
Female	12	7	
Previous disease history (%)			
Hypertension			
Male	3 (9.4)	12 (80.0)	0.3781
Female	4 (33.3)	6 (85.7)	
Diabetes mellitus			
Male	5 (16.0)	7 (47.0)	0.6668
Female	3 (25.0)	5 (71.4)	
Urinary tract infections			
Male	4 (12.5)	5 (33.3)	0.6563
Female	6 (50.0)	4 (57.1)	
Family bladder cancer history			
Male	4 (12.5)	5 (33.3)	0.4909
Female	0 (0.0)	2 (29.0)	
Smoking			
Male	22 (68.7)	14 (93.3)	0.6327
Female	2 (16.6)	5 (71.4)	
Actively smoking	24 (55.0)	19 (86.3)	0.0135 ^b
Non-smoking	20 (45.4)	3 (14.0)	
Smoke-free environment ^a	15 (75.0)	0 (0.0)	0.0316 ^b
Passive smoking	5 (25.0)	3 (100.0)	


^aThe percentage of patients in a smoke-free environment of all non-smoking patients. ^bP-value <0.05.

Figure 2. Comparison of Cav-1 and DNM2 expression in low- and high-grade tumor tissues using the Wilcoxon test. ****P<0.0001. Cav-1, caveolin-1; DNM2, dynamin-2.

cancer cell lines (39,41). The genes exhibited enhanced expression levels in bladder tumor samples concomitantly with the progression of cancer. A significant difference in expression levels was observed comparing between low- and high-grade tumors (P<0.0001; Fig. 2). A similar trend was




Figure 3. Stage-wise comparison in the expression of (A) Cav-1 and (B) DNM2 in tumor samples. Overall statistical significance was determined using one way analysis of variance followed by Tukey's post-hoc test. **** $P < 0.0001$. Cav-1, caveolin-1; DNM2, dynamin-2.




Figure 4. Correlation analysis of the expression levels of Cav-1 and DNM2 in (A) the adjacent normal bladder tissue ($r = 0.32$; $P = 0.05$) and (B) the tumor samples ($r = 0.80$; $P < 0.0001$). Cav-1, caveolin-1; DNM2, dynamin-2.

also observed with respect to the cancer stages. Alterations in *Cav-1* and *DNM2* expression were revealed to be associated with the cancer stage, as indicated in Fig. 3A and B. These results demonstrated that the expression levels of the two genes increased concomitantly with the development of higher disease stages. However, highly significant differences in the expression of Cav-1 and DNM2 were observed when stage I tumors were compared with stage II tumors ($P < 0.0001$), and when stage II tissues were compared with stage III samples ($P < 0.0001$). A similar difference was also identified when comparing stage I tumors with stage III tumors ($P < 0.0001$; Fig 3A and B).

Correlation between Cav-1 and DNM2. The *Cav-1* and *DNM2* genes serve an important role in the functionality of clathrin-independent endocytosis. Altered expression levels of the genes has been demonstrated to be associated with pathological outcomes (32,47). In the present study, the expression of *Cav-1* was clearly correlated with the expression of *DNM2* ($P < 0.0001$; Pearson's coefficient, $r = 0.8617$; Fig. 4A and B). The segregation of DNM1/Cav-1 correlation data into two clusters additionally confirmed the increased expression of the 2

genes in high-grade tumors compared with low-grade tumors demonstrated in Fig. 2.

Discussion

Cav-1 is a key component of caveolae in terms of their formation, arrangement and function. Together with *DNM2*, *Cav-1* initiates the process of endocytosis (32). *Cav-1* has been demonstrated to be a critical component of numerous types of cancer, including breast, lung, colorectal, cervical and pancreatic cancer (21,48-50). Previous studies have presented accumulating evidence revealing that cancer cells are prone to modifying the microenvironment of the tumor, inducing the adjacent cells to become malignant (51-54). In this regard, *Cav-1* is implicated as an important protein that affects the metabolic activity of cells during cancer progression (55). The results of the present study revealed a progressive increase in the expression level of *Cav-1* concomitant with the higher stages of bladder cancer. As the stage of bladder cancer progresses, cells that are cancerous maintain their survival by utilizing key proteins that provide them with the necessarily favorable environment to grow, invade and migrate via regulating the

respective functional proteins. Increased expression levels of *Cav-1* in higher grades of bladder cancer enable an increased potential of the cells to invade and proliferate (56). Therefore, in the present study, the high-grade tumors were revealed to have comparatively enhanced expression levels of *Cav-1* compared with low-grade tumors.

Altered expression of *DNM2* also serves a role in cancer progression. *DNM2* has been implicated as a therapeutic target for cervical cancer: In HeLa cells, dynamin-2 inhibitors have been demonstrated to cause decreased migration and invasion via decreasing the expression of matrix metalloproteinase 9, thereby lowering the rate of cell proliferation (57). Similar to *Cav-1*, an increase in the expression of *DNM2* has been demonstrated to correspond to advances in the tumor stage (19). In the present study, the expression levels of *DNM2* and *Cav-1* genes exhibited a marked correlation with the progression of bladder tumor stage. These results demonstrated that an increase in the expression of these 2 genes may stimulate the tumors to proliferate, invade and metastasize to different adjacent organs. Cancer cells have their own modified microenvironment through which they communicate with adjacent cells for growth proliferation and survival (5).

Summarizing what is known concerning cancer progression, cellular communication is the hallmark of tumorigenesis. Interactions with signaling molecules provide a major focus for disrupted signaling. *Cav-1*, being a key protein of the caveolae, is critical for cancer development, as it directly interacts with signaling proteins, including phosphoinositide 3-kinase, Src, phospholipases, extracellular signal-regulated kinase, G-proteins, endothelial nitric oxide synthase, adenylyl cyclase, protein kinase C, p53 and cell division control protein 42 homolog, and is involved in signal transduction cascades (13,58,59). Dysfunction of *Cav-1*, resulting from the aberrant expression of the gene, triggers the activation of various growth-promoting pathways (4,11). Previous studies have suggested overexpression of *Cav-1* to be a cause of cancer progression (32,60,61). Similarly, together with *Cav-1*, *DNM2* also mediates effects on cancer formation and progression. The 2 proteins are involved in the endocytosis of a number of receptor proteins, ligands and signaling molecules (19,62). However, it has been suggested that there are several other interlinked signaling pathways that, in response to overexpression of *Cav-1* and *DNM2*, may be activated and/or deactivated, resulting in tumor formation (63).

Although the present study has described the genetic expression of the target genes, there were several limitations. Firstly, the samples were not obtained from stages 0a and 0is, the 2 preliminary stages of bladder cancer, or the final stage, stage IV, as patients are not subjected to TURBT at the initial or the last stages of disease. Consequently, all the patients within the study cohort were diagnosed with mid-stage disease, for which TURBT surgery is available. There is an urgent requirement for diagnoses of bladder cancer at early stages. The target genes selected for the present study may be considered as good prognostic marker for bladder cancer. If bladder tumor samples from the initial to the final stages had been available for analysis, then the differences in expression of the target genes in the tumor samples could have been validated more comprehensively. Future studies will aim to

investigate the protein expression of the target genes in bladder tumor samples, and to explore the functional disruptions due to overexpression of the target genes/proteins that may have caused tumor aggressiveness during cancer progression. In the present study, the observed association of the increased expression levels of *Cav-1* and *DNM2* with advancing tumor stage could be considered as a risk factor for bladder cancer, which may additionally aid tumor and disease prognosis, and provide potentially novel treatment options.

Acknowledgements

Not applicable.

Funding

The present study was supported by the COMSATS Research Grant Program (grant no. 16/54/CRGP/CIIT/IBD/15/791) by COMSATS University Islamabad.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

SAR was responsible for conception and design of the study, performed the data analysis and its interpretation, and prepared the manuscript. STAS refined the research design, and performed data analysis and interpretation. KS assisted with the experimental protocols and data acquisition. AY, AK, MN and AM evaluated the tumor samples and prepared the histopathological reports of the tumors. AT and NB contributed towards the research design, and secured collaborations with the hospitals from which the samples were obtained. MJK and AH also assisted with the conception of the study, and with research supervision.

Ethics approval and consent to participate

The study was approved by the ethical review board of COMSATS Institute of Information Technology (approval no. CIIT/Bio/ERB/18/76). Written signed consent was obtained from the patients involved.

Patient consent for publication

Written signed consent was obtained from the patients involved.

Competing interests

The authors declare that they have no competing interests.

References

1. Bastiani M and Parton RG: Caveolae at a glance. *J Cell Sci* 123: 3831-3836, 2010.
2. Anderson RG: The Caveolae membrane system. *Annu Rev Biochem* 67: 199-225, 1998.

3. Yamada E: The fine structure of the gall bladder epithelium of the mouse. *J Biophys Biochem Cytol* 1: 445-458, 1955.
4. Cheng JPX and Nichols BJ: Caveolae: One function or many? *Trends Cell Biol* 26: 177-189, 2016.
5. Martinez-Outschoorn UE, Sotgia F and Lisanti MP: Caveolae and signalling in cancer. *Nat Rev Cancer* 15: 225-237, 2015.
6. Parton RG and Pozo MA: Caveolae as plasma membrane sensors, protectors and organizers. *Nat Rev Mol Cell Biol* 14: 98-112, 2013.
7. Ludwig A, Howard G, Mendoza-Topaz C, Deerinck T, Mackey M, Sandin S, Ellisman MH and Nichols BJ: Molecular composition and ultrastructure of the caveolar coat complex. *PLoS Biol* 11: e1001640, 2013.
8. Patel HH, Murray F and Insel PA: Caveolae as organizers of pharmacologically relevant signal transduction molecules. *Annu Rev Pharmacol Toxicol* 48: 359-391, 2008.
9. Yao Q, Chen J, Cao H, Orth JD, McCaffery JM, Stan RV and McNiven MA: Caveolin-1 interacts directly with dynamin-2. *J Mol Biol* 348: 491-501, 2005.
10. Mayor S, Parton RG and Donaldson JG: Clathrin-independent pathways of endocytosis. *Cold Spring Harb Perspect Biol* 6: a016758, 2014.
11. Liu P, Rudick M and Anderson RG: Multiple functions of caveolin-1. *J Biol Chem* 277: 41295-41298, 2002.
12. Urra H, Torres VA, Ortiz RJ, Lobos L, Díaz MI, Díaz N, Härtel S, Leyton L and Quest A: Caveolin-1-enhanced motility and focal adhesion turnover require tyrosine-14 but not accumulation to the rear in metastatic cancer cells. *PLoS One* 7: e33085, 2012.
13. Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, *et al*: Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. *Sci Rep* 5: 10867, 2015.
14. Hinshaw JE: Dynamin and its role in membrane fission. *Annu Rev Cell Dev Biol* 16: 483-519, 2000.
15. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene* 366: 2-16, 2006.
16. Basu Roy UK, Rial NS, Kachel KL and Gerner EW: Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. *Mol Carcinog* 47: 538-553, 2008.
17. Feng H, Liu KW, Guo P, Zhang P, Cheng T, McNiven MA, Johnson GR, Hu B and Cheng SY: Dynamin 2 mediates PDGFR α -SHP-2-promoted glioblastoma growth and invasion. *Oncogene* 31: 2691-2702, 2012.
18. Eppinga RD, Krueger EW, Weller SG, Zhang L, Cao H and McNiven MA: Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. *Oncogene* 31: 1228-1241, 2012.
19. Meng J: Distinct functions of dynamin isoforms in tumorigenesis and their potential as therapeutic targets in cancer. *Oncotarget* 8: 41701-41716, 2017.
20. Alshenawy HA and Ali MA: Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin-beta-catenin complex. *Ann Diagn Pathol* 17: 476-482, 2013.
21. Patlolla JM, Swamy MV, Raju J and Rao CV: Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. *Oncol Rep* 11: 957-963, 2004.
22. Tanase CP: Caveolin-1: A marker for pancreatic cancer diagnosis. *Expert Rev Mol Diagn* 8: 395-404, 2008.
23. Sarwar MR and Saqib A: Cancer prevalence, incidence and mortality rates in Pakistan in 2012. *Cogent Med* 4: 1288773, 2017.
24. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, *et al*: Comprehensive molecular characterization of muscle-invasive bladder cancer. *Cell* 171: 540-556.e525, 2017.
25. Zhang X and Zhang Y: Bladder cancer and genetic mutations. *Cell Biochem Biophys* 73: 65-69, 2015.
26. Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu L, Ge N, Liu J, Wang C, Ren H, *et al*: TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. *Oncologist* 20: 263-269, 2015.
27. Zhao M, He XL and Teng XD: Understanding the molecular pathogenesis and prognostics of bladder cancer: An overview. *Chin J Cancer Res* 28: 92-98, 2016.
28. Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kälkner KM, Nilsson S, Valdman A and Ullén A: Current status of prognostic immunohistochemical markers for urothelial bladder cancer. *Tumour Biol* 29: 311-322, 2008.
29. Sever R and Brugge JS: Signal transduction in cancer. *Cold Spring Harb Perspect Med* 5: a006098, 2015.
30. Massey KA and Schnitzer JE: Caveolae and cancer. *Recent Results Cancer Res* 180: 217-231, 2010.
31. Gupta R, Toufaily C and Annabi B: Caveolin and cavin family members: Dual roles in cancer. *Biochimie* 107: 188-202, 2014.
32. Chen D and Che G: Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (review). *Oncol Lett* 8: 1409-1421, 2014.
33. Soria F, Lucca I, Moschini M, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Gust KM, Hassler MR, *et al*: Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. *Urol Oncol* 35: 356-362, 2017.
34. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F and Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. *J Clin Oncol* 24: 778-789, 2006.
35. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS and Goodison S: Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. *Cancer Epidemiol Biomarkers Prev* 18: 444-453, 2009.
36. Dyrskjot L, Zieger K, Kruhoffer M, Thykjaer T, Jensen JL, Primdahl H, Aziz N, Marcussen N, Möller K and Orntoft TF: A molecular signature in superficial bladder carcinoma predicts clinical outcome. *Clin Cancer Res* 11: 4029-4036, 2005.
37. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, *et al*: Melanoma staging: Evidence-based changes in the American Joint Committee on cancer eighth edition cancer staging manual. *CA Cancer J Clin* 67: 472-492, 2017.
38. Pan CC and Chang YH: The 2004 World Health Organization/International Society of Urological Pathology classification system for non-muscle-invasive bladder cancer. *Urol Sci* 24: 96-100, 2013.
39. Zhang Y, Nolan M, Yamada H, Watanabe M, Nasu Y, Takei K and Takeda T: Dynamin2 GTPase contributes to invadopodia formation in invasive bladder cancer cells. *Biochem Biophys Res Commun* 480: 409-414, 2016.
40. Ruan J and Weng ZL: Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma. *Zhonghua Zhong Liu Za Zhi* 32: 429-431, 2010 (In Chinese).
41. Liang W, Hao Z, Han JL, Zhu DJ, Jin ZF and Xie WL: CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition. *Urol Oncol* 32: 855-863, 2014.
42. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buysyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, *et al*: Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 15: 1240-1267, 2017.
43. Rio DC, Ares M Jr, Hannon GJ and Nilsen TW: Purification of RNA using TRIzol (TRI reagent). *Cold Spring Harb Protoc* 2010: pdb.prot5439, 2010.
44. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
45. Bangaru ML, Park F, Hudmon A, McCallum JB and Hogan QH: Quantification of gene expression after painful nerve injury: Validation of optimal reference genes. *J Mol Neurosci* 46: 497-504, 2012.
46. Cancer. Net Editorial Board: Bladder Cancer-Risk Factors. <https://www.cancer.net/cancer-types/bladder-cancer/risk-factors> Accessed: June 25, 2012.
47. Aghbolaghi AG and Lechpammer M: A rare case of centronuclear myopathy with DNM2 mutation: Genotype-phenotype correlation. *Autops Case Rep* 7: 43-48, 2017.
48. Duregon E, Senetta R, Bertero L, Bussolati B, Annaratone L, Pittaro A, Papotti M, Marchiò C and Cassoni P: Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. *Tumour Biol* 39: 1010428317694311, 2017.
49. Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. *Oncogene* 16: 1391-1397, 1998.

50. Lin M, DiVito MM, Merajver SD, Boyanapalli M and van Golen KL: Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and Caveolin-1. *Mol Cancer* 4: 21, 2005.
51. Friedl P and Alexander S: Cancer invasion and the microenvironment: Plasticity and reciprocity. *Cell* 147: 992-1009, 2011.
52. Kang HW, Kim WJ and Yun SJ: The role of the tumor microenvironment in bladder cancer development and progression. *Transl Cancer Res* 6 (Suppl): S744-S758, 2017.
53. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S and Lisanti MP: Caveolin-1 and cancer metabolism in the tumor microenvironment: Markers, models, and mechanisms. *Annu Rev Pathol* 7: 423-467, 2012.
54. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, *et al*: Role of tumor microenvironment in tumorigenesis. *J Cancer* 8: 761-773, 2017.
55. Nwosu ZC, Ebert MP, Dooley S and Meyer C: Caveolin-1 in the regulation of cell metabolism: A cancer perspective. *Mol Cancer* 15: 71, 2016.
56. Diaz-Valdivia N, Bravo D, Huerta H, Henriquez S, Gabler F, Vega M, Romero C, Calderon C, Owen GI, Leyton L and Quest AF: Enhanced caveolin-1 expression increases migration, anchorage-independent growth and invasion of endometrial adenocarcinoma cells. *BMC Cancer* 15: 463, 2015.
57. Girard E, Paul JL, Fournier N, Beaune P, Johannes L, Lamaze C and Védie B: The Dynamin Chemical Inhibitor Dynasore Impairs Cholesterol Trafficking and Sterol-Sensitive Genes Transcription in Human HeLa Cells and Macrophages. *PLoS One* 6: e29042, 2011.
58. Lee YY, Jeon HK, Lee J, Do IG, Choi CH, Kim TJ, Kim BG, Bae DS, Kim YC and Lee JW: Dynamin 2 inhibitors as novel therapeutic agents against cervical cancer cells. *Anticancer Res* 36: 6381-6388, 2016.
59. Galbiati F, Volonte D, Liu J, Capozza F, Frank PG, Zhu L, Pestell RG and Lisanti MP: Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. *Mol Biol Cell* 12: 2229-2244, 2001.
60. Nunez-Wehinger S, Ortiz RJ, Diaz N, Diaz J, Lobos-Gonzalez L and Quest AF: Caveolin-1 in cell migration and metastasis. *Curr Mol Med* 14: 255-274, 2014.
61. Sun DS, Hong SA, Won HS, Yoo SH, Lee HH, Kim O and Ko YH: Prognostic value of metastatic tumoral caveolin-1 expression in patients with resected gastric cancer. *Gastroenterol Res Pract* 2017: 5905173, 2017.
62. Ge Z, Gu Y, Han Q, Zhao G, Li M, Li J, Chen B, Sun T, Dovat S, Gale RP and Song C: Targeting HIGH DYNAMIN-2 (DNM2) expression by restoring ikaros function in acute lymphoblastic leukemia. *Sci Rep* 6: 38004, 2016.
63. Quest AF, Gutierrez-Pajares JL and Torres VA: Caveolin-1: An ambiguous partner in cell signalling and cancer. *J Cell Mol Med* 12: 1130-1150, 2008.